Jafron BiomedicalLtd Balance Sheet Health
Financial Health criteria checks 5/6
Jafron BiomedicalLtd has a total shareholder equity of CN¥3.3B and total debt of CN¥1.6B, which brings its debt-to-equity ratio to 49.1%. Its total assets and total liabilities are CN¥5.6B and CN¥2.3B respectively. Jafron BiomedicalLtd's EBIT is CN¥933.7M making its interest coverage ratio -95.3. It has cash and short-term investments of CN¥2.7B.
Key information
49.1%
Debt to equity ratio
CN¥1.62b
Debt
| Interest coverage ratio | -95.3x |
| Cash | CN¥2.71b |
| Equity | CN¥3.29b |
| Total liabilities | CN¥2.30b |
| Total assets | CN¥5.59b |
Recent financial health updates
Recent updates
Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%
Oct 21
Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce
Oct 02Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
Sep 09The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence
Aug 25Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40
May 28A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)
May 24Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge
May 08Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture
May 02Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital
Apr 13Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?
Mar 22Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce
Mar 04Financial Position Analysis
Short Term Liabilities: 300529's short term assets (CN¥3.3B) exceed its short term liabilities (CN¥872.9M).
Long Term Liabilities: 300529's short term assets (CN¥3.3B) exceed its long term liabilities (CN¥1.4B).
Debt to Equity History and Analysis
Debt Level: 300529 has more cash than its total debt.
Reducing Debt: 300529's debt to equity ratio has increased from 0% to 49.1% over the past 5 years.
Debt Coverage: 300529's debt is well covered by operating cash flow (74.1%).
Interest Coverage: 300529 earns more interest than it pays, so coverage of interest payments is not a concern.